CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
53.15
+0.53 (1.01%)
At close: Jan 21, 2025, 4:00 PM
53.24
+0.09 (0.17%)
After-hours: Jan 21, 2025, 7:46 PM EST
CVS Health Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for CVS Health stock have an average target of 69.25, with a low estimate of 58 and a high estimate of 86. The average target predicts an increase of 30.29% from the current stock price of 53.15.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CVS Health stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 6 |
| Buy | 6 | 5 | 7 | 7 | 7 | 7 |
| Hold | 7 | 7 | 5 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 18 | 18 | 17 | 17 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $67 → $60 | Strong Buy | Maintains | $67 → $60 | +12.89% | Jan 6, 2025 |
| Deutsche Bank | Deutsche Bank | Hold → Strong Buy Upgrades $66 | Hold → Strong Buy | Upgrades | $66 | +24.18% | Dec 3, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $73 → $80 | Strong Buy | Maintains | $73 → $80 | +50.52% | Nov 25, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $72 → $64 | Buy | Maintains | $72 → $64 | +20.41% | Nov 25, 2024 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $76 → $67 | Strong Buy | Reiterates | $76 → $67 | +26.06% | Nov 20, 2024 |
Financial Forecast
Revenue This Year
375.62B
from 356.62B
Increased by 5.33%
Revenue Next Year
391.31B
from 375.62B
Increased by 4.18%
EPS This Year
5.32
from 6.47
Decreased by -17.82%
EPS Next Year
6.21
from 5.32
Increased by 16.72%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 393.2B | 422.6B | 455.9B | |||
| Avg | 375.6B | 391.3B | 411.1B | |||
| Low | 360.6B | 363.1B | 371.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 10.3% | 12.5% | 16.5% | |||
| Avg | 5.3% | 4.2% | 5.1% | |||
| Low | 1.1% | -3.3% | -5.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 6.11 | 7.86 | 8.46 | |||
| Avg | 5.32 | 6.21 | 7.15 | |||
| Low | 4.59 | 5.15 | 5.90 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.5% | 47.9% | 36.4% | |||
| Avg | -17.8% | 16.7% | 15.3% | |||
| Low | -29.1% | -3.1% | -4.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.